We are live on ! Find out more
LIPO

Lipella Pharmaceuticals
LIPO

Delisted

LIPO was delisted on the 18th of June, 2025.

Back to rankings

4 hedge funds and large institutions have $82.5K invested in Lipella Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.26% less ownership

Funds ownership: 0.93% → 0.67% (-0.26%)

20% less capital invested

Capital invested by funds: $104K → $82.5K (-$21.1K)

33% less funds holding

Funds holding: 6 → 4 (-2)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Holders
4
Holders Change
-2
Holders Change %
-33.33%
% of All Funds
0.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$3.14K

Top Sellers

Rank Fund Capital Flow
1
TSS
Two Sigma Securities
New York
-$25.6K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$4.98K
3
TRCT
Tower Research Capital (TRC)
New York
-$1.19K
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$100

LIPO Hedge Fund Activity: Q2 2023 in Review

4 of the 6,384 institutional investors tracked by Wall St. Rank reported a position in Lipella Pharmaceuticals (LIPO) for Q2 2023, worth a combined $82.5K — down 20% from $104K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of LIPO and 0 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 1 added.

The largest buyer was UBS Group, adding an estimated $3.14K. The largest seller was Two Sigma Securities, exiting entirely with an estimated $25.6K sold.

  • 4 institutional investors held Lipella Pharmaceuticals (LIPO) as of Q2 2023, down from 6 in Q1 2023.
  • Funds reported $82.5K of Lipella Pharmaceuticals stock for Q2 2023, down 20% quarter-over-quarter.
  • 0 funds opened new Lipella Pharmaceuticals positions in Q2 2023 and 2 closed out, a net change of -2 holders.
  • The largest Lipella Pharmaceuticals buyer in Q2 2023 was UBS Group, an estimated $3.14K added.
  • The largest Lipella Pharmaceuticals seller in Q2 2023 was Two Sigma Securities, an estimated $25.6K sold.

Based on aggregated 13F filings for Q2 2023.